The patient experienced low-grade hypercalcaemia and hyperphosphataemia: these derive from inhibition of FGFR1 (most compounds in late clinical development have pan-FGFR-inhibitory activity; FGFR2-selective agents are in early drug development). Here, FGFR1 is linked to hyperphosphatemia.